These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8004315)

  • 21. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 22. The impact of genotype on endocrine complications in thalassaemia major.
    Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
    Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary function abnormalities in thalassemia patients on a hypertransfusion program.
    Keens TG; O'Neal MH; Ortega JA; Hyman CB; Platzker AC
    Pediatrics; 1980 May; 65(5):1013-7. PubMed ID: 7367114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulmonary functions in Egyptian children with transfusion-dependent β-thalassemia.
    Abd El Hakeem AA; Mousa SMO; AbdelFattah MT; AbdelAziz AO; Abd El Azeim SS
    Transfus Med; 2019 Feb; 29(1):55-60. PubMed ID: 30779248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease.
    Porter JB
    Hemoglobin; 2009; 33 Suppl 1():S37-45. PubMed ID: 20001631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
    Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
    Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary function test in transfusion-dependent beta-thalassemia patients.
    Azarkeivan A; Mehrvar A; Pour HS; Mehrvar N; Vosough P
    Pediatr Hematol Oncol; 2008 Sep; 25(6):598-606. PubMed ID: 18728979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pituitary iron and volume predict hypogonadism in transfusional iron overload.
    Noetzli LJ; Panigrahy A; Mittelman SD; Hyderi A; Dongelyan A; Coates TD; Wood JC
    Am J Hematol; 2012 Feb; 87(2):167-71. PubMed ID: 22213195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C; Ortega Aramburu JJ; Alonso JL; Albisu M; Casaldáliga J; Díaz de Heredia C; Olivé T; Bastida P
    Med Clin (Barc); 1994 May; 102(19):721-4. PubMed ID: 8041200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
    Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
    Farmaki K; Tzoumari I; Pappa C
    Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.